A Comprehensive Analysis of C4orf19: A Potential Drug Target and Biomarker

Target Name: C4orf19

NCBI ID: G55286

C4orf19

Other Name(s): CD019_HUMAN | C4orf19 variant 1 | chromosome 4 open reading frame 19 | Uncharacterized protein C4orf19 | Chromosome 4 open reading frame 19, transcript variant 1

A Comprehensive Analysis of C4orf19: A Potential Drug Target and Biomarker

Abstract:
C4orf19, also known as CD019, has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. This article will provide an in-depth analysis of C4orf19, including its structure, function, and potential therapeutic applications.

Introduction:
C4orf19, a non-coding RNA molecule, has been identified as a potential drug target and biomarker for various diseases. Its unique structure and diverse functions have made it an attractive target for researchers to investigate. C4orf19 is expressed in various tissues and cells in the human body and has been associated with various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases.

Structure and Function:
C4orf19 is a small non-coding RNA molecule that consists of 218 amino acid residues. It has a unique structure, with a 13-amino acid loop at its C-terminus and a 128-amino acid loop at its N-terminus. This looped structure gives C4orf19 a unique shape and allows it to interact with various proteins.

C4orf19 functions as a negative regulator of the expression of its target genes. It interacts with the protein encoded by the gene CD163, which is a cell adhesion molecule that plays a role in various physiological processes, including cell signaling and tissue organization. By interacting with CD163, C4orf19 has been shown to regulate the expression of genes involved in cell adhesion, migration, and invasion.

Potential Therapeutic Applications:
C4orf19 has been shown to be a potential drug target for various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. Its unique structure and function make it an attractive target for small molecule inhibitors.

In the context of cancer, C4orf19 has been shown to be involved in the regulation of cell adhesion and migration. Several studies have shown that C4orf19 interacts with CD163 and that inhibition of its expression can lead to the downregulation of CD163, which in turn can lead to the inhibition of cell adhesion and migration. This suggests that C4orf19 may be an effective target for cancer therapies that target cell adhesion and migration.

In the context of neurodegenerative disorders, C4orf19 has been shown to be involved in the regulation of neurotransmitter synthesis and release. Several studies have shown that C4orf19 interacts with the neurotransmitter receptor encoded by the gene GABA, which plays a role in modulating neurotransmitter synthesis and release. This suggests that C4orf19 may be an effective target for neurodegenerative disorders therapies that target neurotransmitter synthesis and release.

In the context of autoimmune diseases, C4orf19 has been shown to be involved in the regulation of immune cell function. Several studies have shown that C4orf19 interacts with the immune checkpoint receptor encoded by the gene PD-1, which plays a role in regulating immune cell function. This suggests that C4orf19 may be an effective target for autoimmune diseases therapies that target immune cell function.

Conclusion:
In conclusion, C4orf19 is a unique non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases. Its unique structure and diverse functions make it an attractive target for small molecule inhibitors. Further research is needed to fully understand the role of C4orf19 in various diseases and to develop effective therapies that target its unique properties.

Protein Name: Chromosome 4 Open Reading Frame 19

The "C4orf19 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about C4orf19 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets